Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
前收盤價
US$103
−US$0.87 · -0.84%
盤中時間採用ET。市場資料可能有所延遲。
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
日內區間
目前US$103
52週區間
目前US$103
盤中時間採用ET。市場資料可能有所延遲。
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
日內區間
目前US$103
52週區間
目前US$103
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 443.28億 USD | 419.5億 USD | 401.09億 USD | 436.53億 USD | 430.75億 USD |
| 銷貨成本 | 197.21億 USD | 206.25億 USD | 200.72億 USD | 213.3億 USD | 198.61億 USD |
| 毛利 | 246.07億 USD | 213.25億 USD | 200.37億 USD | 223.23億 USD | 232.14億 USD |
| 研究與開發 | 29.55億 USD | 28.23億 USD | 27.19億 USD | 28.52億 USD | 27.38億 USD |
| 銷售、一般及管理費用 | 123.78億 USD | 116.51億 USD | 108.83億 USD | 111.09億 USD | 112.76億 USD |
| 營業費用 | 165.86億 USD | 144.74億 USD | 136.02億 USD | 139.61億 USD | 140.14億 USD |
| 利息收入 | 2.3億 USD | 3.44億 USD | 3.85億 USD | 1.83億 USD | 4300萬 USD |
| 利息支出 | 3.41億 USD | 6.03億 USD | 6.98億 USD | 3.15億 USD | 4.1億 USD |
| 折舊和攤銷 | 31.16億 USD | 32.18億 USD | 32.43億 USD | 32.67億 USD | 35.38億 USD |
| 營業利益 | 80.48億 USD | 68.25億 USD | 64.35億 USD | 83.62億 USD | 92億 USD |
| 淨利 | 65.24億 USD | 134.02億 USD | 57.23億 USD | 69.33億 USD | 70.71億 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$120.85
上漲空間 17.33%年度分割調整後的每股現金分配。
US$2.36
2025年(完整年度)+31.1% 自從 2021
2026年(部分年度):US$2.52
US$1.80
2,021
US$1.88
2,022
US$2.04
2,023
US$2.20
2,024
US$2.36
2,025
US$2.52
2,026*
* 在現有股息歷史記錄中,該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年10月15日 | US$0.63Quarterly | 2026年10月15日 | 2026年11月16日 |
股息 | 2026年7月15日 | US$0.63Quarterly | 2026年7月15日 | 2026年8月17日 |
股息 | 2026年4月15日 | US$0.63Quarterly | 2026年4月15日 | 2026年5月15日 |
股息 | 2026年1月15日 | US$0.63Quarterly | 2026年1月15日 | 2026年2月13日 |
股息 | 2025年10月15日 | US$0.59Quarterly | 2025年10月15日 | 2025年11月17日 |
股息 | 2025年7月15日 | US$0.59Quarterly | 2025年7月15日 | 2025年8月15日 |
除息 2026年10月15日
US$0.63
Quarterly
2026年10月15日登記 · 支付日 2026年11月16日
除息 2026年7月15日
US$0.63
Quarterly
2026年7月15日登記 · 支付日 2026年8月17日
除息 2026年4月15日
US$0.63
Quarterly
2026年4月15日登記 · 支付日 2026年5月15日
除息 2026年1月15日
US$0.63
Quarterly
2026年1月15日登記 · 支付日 2026年2月13日
除息 2025年10月15日
US$0.59
Quarterly
2025年10月15日登記 · 支付日 2025年11月17日
除息 2025年7月15日
US$0.59
Quarterly
2025年7月15日登記 · 支付日 2025年8月15日
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T3473.08億0.29%119.93兆 JPY0.09%¥113,700-3.19%
Vanguard S&P 500 ETFVOO48.83億0.28%1兆 USD0.03%US$635.54-3.41%
Vanguard Morningstar Total Stock Market ETFVTI46.05億0.25%6893億 USD0.03%US$340.02-3.52%
Schwab U.S. Dividend Equity ETFSCHD45.07億3.83%1175.2億 USD0.06%US$33.94-0.76%
iShares Core S&P 500 ETFIVV23.98億0.30%8034.1億 USD0.03%US$693.71-3.52%
State Street SPDR S&P 500 ETFSPY21.9億0.29%7563.79億 USD0.09%US$689.81-3.64%
Vanguard Morningstar Value ETFVTV17.66億0.66%1959億 USD0.03%US$214.22-1.62%
State Street Health Care Select Sector SPDR ETFXLV13.11億2.79%469.2億 USD0.08%US$177.24-0.12%
State Street SPDR S&P 500 ETF1557.T
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Total Stock Market ETFVTI
Schwab U.S. Dividend Equity ETFSCHD
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
State Street Health Care Select Sector SPDR ETFXLVAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。